15727231

Source:http://linkedlifedata.com/resource/pubmed/id/15727231

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0016884, umls-concept:C0026769, umls-concept:C0337810, umls-concept:C1833334, umls-concept:C2603343
pubmed:dateCreated	2005-2-24
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/100959175
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Immunologic Factors, http://linkedlifedata.com/resource/pubmed/chemical/Interferon-beta
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	1590-1874
pubmed:author	pubmed-author:FilippiMM, pubmed-author:GhezziAA, pubmed-author:MaD PDP, pubmed-author:RuggieroGG, pubmed-author:TrojanoMM
pubmed:issnType	Print
pubmed:volume	25 Suppl 4
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	S346-9
pubmed:dateRevised	2007-11-15
pubmed:meshHeading	pubmed-meshheading:15727231-Age of Onset, pubmed-meshheading:15727231-Child, pubmed-meshheading:15727231-Child, Preschool, pubmed-meshheading:15727231-Disability Evaluation, pubmed-meshheading:15727231-Female, pubmed-meshheading:15727231-Follow-Up Studies, pubmed-meshheading:15727231-Forecasting, pubmed-meshheading:15727231-Humans, pubmed-meshheading:15727231-Immunologic Factors, pubmed-meshheading:15727231-Interferon-beta, pubmed-meshheading:15727231-Italy, pubmed-meshheading:15727231-Male, pubmed-meshheading:15727231-Multiple Sclerosis, pubmed-meshheading:15727231-Treatment Outcome
pubmed:year	2004
pubmed:articleTitle	Italian studies on early-onset multiple sclerosis: the present and the future.
pubmed:affiliation	Centro Studi Sclerosi Multipla, Ospedale di Gallarate, Via Pastori 4, I-21013 Gallarate, Italy. centro.sm@libero.it
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II